Difelikefalin

Cara Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 7, 2023
Acceleration, ESRD, Drug, CMS, EU, Chronic kidney disease, Civil service commission, Centers for Medicare & Medicaid Services, Conference call, Nephrology, Medicines and Healthcare products Regulatory Agency, Clinical trial, Canaccord Genuity, Notalgia paresthetica, CSL Vifor, Atopic dermatitis, Part, KIND, CSL, EDT, Sale, Medication, Pharmaceuticals and Medical Devices Agency, Dialysis, Net, Medicare, Patient, Investment, Administration, PMDA, Itch, NP, Prospective payment system, Research and development, Research, Therapy, R, CKD, Internal, Conference, European Commission, Kidney, Life insurance, Pharmaceutical industry, Cryptocurrency, Difelikefalin

“In the second quarter of 2023, the commercialization of KORSUVA® (difelikefalin) injection in the U.S. and Kapruvia® in countries around the world continued to make meaningful progress.

Key Points: 
  • “In the second quarter of 2023, the commercialization of KORSUVA® (difelikefalin) injection in the U.S. and Kapruvia® in countries around the world continued to make meaningful progress.
  • All three trials are enrolling patients and the internal readout from Part A of our KIND Phase 3 program in AD is expected in the fourth quarter of 2023.
  • Wholesalers shipped 66,852 vials to dialysis centers, the majority of which were Fresenius clinics, during the second quarter of 2023.
  • In the second quarter of 2023, Kapruvia generated $1.2 million in net sales and the Company recorded $123,000 in royalty revenue associated with Kapruvia sales in Europe.

Cara Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Acceleration, Chronic kidney disease, Conference call, Nephrology, Medicines and Healthcare products Regulatory Agency, G&A, Atopic dermatitis, CSL Vifor, CSL, Cara, EDT, Sale, Medication, Pharmaceuticals and Medical Devices Agency, Dialysis, Dermatology, Patient, Investment, Administration, PMDA, Itch, NP, Biophysical environment, ESG, Research and development, Research, R, Therapy, Conference, Pharmaceutical industry, Cryptocurrency, Difelikefalin, Social

STAMFORD, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • – Conference call today at 4:30 p.m. EDT –
    STAMFORD, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2023.
  • “The U.S. and global launches of KORSUVA® (difelikefalin) injection / Kapruvia® gained momentum in the first quarter of 2023.
  • Wholesalers shipped 45,720 vials to dialysis centers, the majority of which were Fresenius clinics, during the first quarter of 2023.
  • Vial orders more than doubled quarter to quarter, signifying an acceleration in patient demand.

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
New Drug Application, Nephrology, Fresenius, Dermatology, Dialysis, Civil service commission, Health care, Chronic kidney disease, Travel, Sale, Patient, KICK, NDD, AD, Itch, Medication, American Academy, Conference call, Research and development, Notalgia paresthetica, Atopic dermatitis, CSL, NP, G&A, CSL Vifor, European Commission, Investment, R, PMDA, KIND, Administration, CKD, Medicines and Healthcare products Regulatory Agency, Cara, Growth, Therapy, Conference, Acceleration, EST, Pharmaceuticals and Medical Devices Agency, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Music, Difelikefalin, EU

STAMFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • During the fourth quarter of 2022, we saw both new clinic and repeat orders driving product uptake, bolstering our confidence in KORSUVA’s long-term potential,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
  • In the fourth quarter of 2022, wholesalers shipped 20,844 vials to dialysis centers following initial inventory building in the third quarter of 2022, predominantly at Fresenius clinics.
  • The Company expects launches in countries in Europe to continue in 2023, following launches of Kapruvia in Austria, Germany, and Sweden during the fourth quarter of 2022.
  • With the approval of Kapruvia in Australia in the fourth quarter of 2022, all four Access Consortium countries have approved the product.

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, August 2, 2021
Life sciences, Drugs, Health sciences, Amines, Antipruritics, Difelikefalin, Piperidines, Biopharmaceutical, Investigational New Drug

ET to report second quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET to report second quarter 2021 financial results and provide a corporate update.
  • To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1568596.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Cara Therapeutics to Present at the Jefferies Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021
Drugs, Amines, Antipruritics, Difelikefalin, Piperidines, Chemistry, Investigational New Drug, Functional groups

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .

Key Points: 
  • A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .
  • An archived webcast recording will be available on the Cara website for approximately 30 days.
  • Cara Therapeuticsis a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Retrieved on: 
Thursday, May 6, 2021
Drugs, Opioid receptors, Branches of biology, Opioid peptides, Antipruritics, Amines, Difelikefalin, Chemistry, κ-opioid receptor, Opioid, Prescription Drug User Fee Act

An archived webcast recording will be available on the Cara website for approximately 30 days.\nCara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.

Key Points: 
  • An archived webcast recording will be available on the Cara website for approximately 30 days.\nCara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
  • Cara is developing a novel and proprietary class of product candidates, led by KORSUVA\xe2\x84\xa2 (CR845/difelikefalin), a first-in-class KOR agonist that targets the body\xe2\x80\x99s peripheral nervous system, as well as certain immune cells.
  • The PDUFA target action date for KORSUVA is August 23, 2021.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.\n'

Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

Retrieved on: 
Monday, May 3, 2021
Drugs, Opioid peptides, Antipruritics, Amines, Difelikefalin, Piperidines, Chemistry, Prescription Drug User Fee Act, Functional groups

ET to report first quarter 2021 financial results and provide a corporate update.\nTo participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 5789617.

Key Points: 
  • ET to report first quarter 2021 financial results and provide a corporate update.\nTo participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 5789617.
  • Cara is developing a novel and proprietary class of product candidates, led by KORSUVA\xe2\x84\xa2 (CR845/difelikefalin), a first-in-class KOR agonist that targets the body\xe2\x80\x99s peripheral nervous system, as well as certain immune cells.
  • The PDUFA target action date for KORSUVA is August 23, 2021.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.\n'

Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Opioid receptors, Drugs, Branches of biology, Opioid peptides, Antipruritics, Amines, Difelikefalin, Chemistry, κ-opioid receptor, Opioid

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .

Key Points: 
  • A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .
  • An archived webcast recording will be available on the Cara website for approximately 30 days.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
  • Difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021

Retrieved on: 
Wednesday, March 31, 2021
Opioid receptors, Drugs, Branches of biology, Opioid peptides, Antipruritics, Amines, Difelikefalin, Chemistry, κ-opioid receptor, Opioid, Kors

STAMFORD, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a virtual research and development (R&D) event on April 7 from 1:00 p.m. to 3:00 p.m.

Key Points: 
  • STAMFORD, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a virtual research and development (R&D) event on April 7 from 1:00 p.m. to 3:00 p.m.
  • The virtual event will include a presentation and interactive Q&A session to explore Caras first-in-class KOR agonist, KORSUVA (difelikefalin), being investigated for the treatment of chronic pruritus in systemic, dermatological, and neurological indications.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
  • Difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Retrieved on: 
Thursday, February 18, 2021
Drugs, Clinical research, Amines, Food and Drug Administration, Antipruritics, Difelikefalin, Chemistry, Investigational New Drug, Functional groups

ET to report fourth quarter and full year 2020 financial results and provide a corporate update.

Key Points: 
  • ET to report fourth quarter and full year 2020 financial results and provide a corporate update.
  • To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 6676157.
  • An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.